IQV · Other

IQVIA HOLDINGS INC.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-09

Revenue Performance and MixImportance 75 · Surprise 60
IQVIA raised its full-year 2026 revenue guidance to US$17.28–US$17.48 billion. The revised outlook was reported alongside the Medera cardiac gene-therapy collaboration, which could support activity in advanced…
Guidance / OutlookImportance 75 · Surprise 60
IQVIA raised its full-year 2026 revenue guidance to US$17.28–US$17.48 billion. The revised outlook indicates a forward revenue range of approximately US$17.4 billion for the year. Third-party reporting also cited…
Acquisition / Partnership / DivestitureImportance 31 · Surprise 42
IQVIA announced a collaboration with Medera Inc. focused on cardiac gene therapies and human-based drug discovery. The alliance combines IQVIA’s clinical-trial execution and commercialization infrastructure with…

Capital Return ProgramImportance 64 · Surprise 42
IQVIA’s board authorized a $2.00 billion share-repurchase program. The authorization was cited alongside quarterly adjusted EPS of $3.15 and revenue of $4.37 billion. Continued buybacks are relevant to capital…
Revenue Performance and MixImportance 34 · Surprise 6
IQVIA reported quarterly revenue of $4.37 billion, while adjusted EPS reached $3.15 and exceeded analyst expectations. The Research & Development Solutions segment generated MXN160.37 billion of the company’s MXN294.03…
Acquisition / Partnership / DivestitureImportance 31 · Surprise 42
IQVIA announced a strategic collaboration with Medera Inc. to advance cardiac gene therapies and human-based drug discovery. IQVIA will contribute clinical-trial infrastructure, while Medera will contribute its…

Revenue Performance and MixImportance 34 · Surprise 6
IQVIA reported quarterly revenue of $4.37 billion, while adjusted EPS reached $3.15 and exceeded analyst expectations. The Research & Development Solutions segment generated MXN160.37 billion of the company’s MXN294.03…

Capital Return ProgramImportance 64 · Surprise 42
IQVIA’s board authorized a $2.00 billion share-repurchase program. The authorization was cited alongside quarterly adjusted EPS of $3.15 and revenue of $4.37 billion. Continued buybacks are relevant to capital…
Revenue Performance and MixImportance 34 · Surprise 6
IQVIA reported quarterly revenue of $4.37 billion, while adjusted EPS reached $3.15 and exceeded analyst expectations. The Research & Development Solutions segment generated MXN160.37 billion of the company’s MXN294.03…
Acquisition / Partnership / DivestitureImportance 31 · Surprise 42
IQVIA announced a strategic collaboration with Medera Inc. to advance cardiac gene therapies and human-based drug discovery. IQVIA will contribute clinical-trial infrastructure, while Medera will contribute its…
Products and TechnologyImportance 31 · Surprise 42
IQVIA and Medera announced a strategic collaboration to accelerate cardiac gene-therapy development and human-based drug discovery. IQVIA will contribute its clinical-trial infrastructure and Medera will contribute its…

Capital Return ProgramImportance 64 · Surprise 42
IQVIA’s board authorized a $2.00 billion share-repurchase program. The authorization was cited alongside quarterly adjusted EPS of $3.15 and revenue of $4.37 billion. Continued buybacks are relevant to capital…
Revenue Performance and MixImportance 34 · Surprise 6
IQVIA reported quarterly revenue of $4.37 billion, while adjusted EPS reached $3.15 and exceeded analyst expectations. The Research & Development Solutions segment generated MXN160.37 billion of the company’s MXN294.03…
Acquisition / Partnership / DivestitureImportance 31 · Surprise 42
IQVIA announced a strategic collaboration with Medera Inc. to advance cardiac gene therapies and human-based drug discovery. IQVIA will contribute clinical-trial infrastructure, while Medera will contribute its…